List of Excipients in Branded Drug YONSA

« Back to Dashboard

YONSA Excipient Strategy and Commercial Opportunities in Abiraterone Acetate

Last updated: September 1, 2026

YONSA is a differentiated abiraterone acetate product built around micronized active pharmaceutical ingredient, a compact 125 mg tablet, and reduced food-effect constraints. Its commercial value is tied less to novel excipient chemistry than to formulation engineering, particle-size control, content uniformity, dissolution performance, and manufacturing reproducibility. The main opportunity for excipient suppliers and generic developers is to reproduce or improve the performance of the formulation while preserving bioequivalence, tablet robustness, low-dose uniformity, and regulatory simplicity.

What is YONSA and how does its formulation differ from ZYTIGA?

YONSA is a 125 mg oral tablet containing micronized abiraterone acetate. The product is approved with methylprednisolone for treatment of metastatic castration-resistant prostate cancer and metastatic high-risk castration-sensitive prostate cancer in specified patient populations. Sun Pharmaceutical Industries markets YONSA in the United States. The original product was developed by Churchill Pharmaceuticals and acquired by Sun Pharma. [1]

The principal distinction from ZYTIGA is administration with or without food. ZYTIGA abiraterone acetate tablets are administered on an empty stomach because food substantially increases abiraterone exposure. YONSA uses micronized abiraterone acetate and may be taken with or without food, according to its FDA-approved labeling. [1,2]

Attribute	YONSA	ZYTIGA
Active ingredient	Abiraterone acetate	Abiraterone acetate
Strength	125 mg	250 mg and 500 mg
Form	Micronized tablet	Conventional tablet
Daily dose	500 mg, four 125 mg tablets	1,000 mg
Food administration	With or without food	Empty stomach
Steroid combination	Methylprednisolone	Prednisone
Key formulation issue	Particle-size-driven dissolution and exposure control	Large food effect
Product category	Small-molecule specialty oncology drug	Small-molecule specialty oncology drug
Biosimilar pathway	Not applicable	Not applicable

The micronized drug substance is the central formulation variable. Excipient selection supports processing and stability but is unlikely to be the primary source of clinical differentiation.

What excipients are used in YONSA tablets?

The FDA prescribing information identifies the principal inactive ingredients as lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxide, and magnesium stearate. The film coating contains standard coating components, including polyvinyl alcohol, titanium dioxide, talc, and coloring agents. Exact supplier grades and quantitative composition are generally controlled within the product’s CMC documentation rather than fully disclosed in the public label. [1]

Functional role	YONSA excipient class	Formulation purpose
Diluent	Lactose monohydrate	Tablet mass and compression support
Diluent and dry binder	Microcrystalline cellulose	Compactibility, hardness, and tablet integrity
Disintegrant	Croscarmellose sodium	Rapid tablet breakup
Wetting or surfactant aid	Sodium lauryl sulfate	Improved wetting of poorly soluble drug particles
Glidant	Colloidal silicon dioxide	Powder flow and blend uniformity
Lubricant	Magnesium stearate	Ejection and prevention of sticking
Film coating	Polyvinyl alcohol, talc, titanium dioxide, iron oxide or equivalent pigments	Protection, appearance, identification, and swallowability

The excipient system is conventional. The technical challenge is the interaction between these excipients and micronized abiraterone acetate. A change in surfactant grade, lubricant concentration, disintegrant level, or lactose morphology can alter wetting, dissolution, tablet tensile strength, and exposure.

Why is micronization more commercially important than excipient novelty?

Abiraterone acetate has low aqueous solubility. Reducing particle size increases surface area and can improve dissolution. In YONSA, micronization reduces the dependence of systemic exposure on meal-related solubilization. The formulation therefore depends on a controlled particle-size distribution rather than simply on a high-solubilization excipient.

Critical material attributes include:

• D10, D50, and D90 particle-size values.
• Particle morphology and agglomeration.
• Specific surface area.
• Crystallinity and polymorphic form.
• Residual solvent and moisture.
• Electrostatic behavior during blending.
• Content uniformity at the 125 mg tablet level.
• Dissolution under fed and fasted conditions.

Particle-size reduction creates manufacturing risks. Micronized powders may have poor flow, high cohesiveness, electrostatic charging, and segregation during hopper transfer. Colloidal silicon dioxide and microcrystalline cellulose can improve flow and compactibility, while sodium lauryl sulfate can improve wetting. Excessive lubricant, particularly magnesium stearate, can create a hydrophobic tablet surface and slow dissolution.

For this reason, a generic developer cannot assume that substituting excipients on a nominally equivalent basis will preserve YONSA performance. Excipient grade, particle size, surface area, moisture content, mixing order, lubrication time, and compression force can all affect the finished product.

What excipient strategies are available for YONSA generic development?

A developer has four practical formulation routes.

1. Close qualitative and quantitative replication

The lowest regulatory-risk strategy is to use the same inactive ingredient classes and, where commercially feasible, comparable grades and concentrations. This approach reduces formulation uncertainty and may simplify comparative dissolution work.

The principal limitations are supplier dependence, potential difficulty sourcing the same functional grades, and the risk that a close composition still performs differently because of process conditions.

2. Surfactant optimization

Sodium lauryl sulfate is relevant because abiraterone acetate is poorly water soluble. A developer could evaluate alternative wetting agents or surfactant levels, including poloxamers, polysorbates, sodium docusate, or other compendial surfactants.

This route has commercial potential but also creates regulatory and quality risks:

• New surfactants can change absorption.
• Higher surfactant levels may cause gastrointestinal tolerability concerns.
• Excipient changes can alter impurity formation or tablet stability.
• A different dissolution mechanism may require more extensive comparative studies.
• Nonstandard excipient use levels may attract FDA review.

A conservative strategy is to optimize sodium lauryl sulfate grade and concentration before replacing it.

3. Direct-compression platform

A direct-compression formulation using microcrystalline cellulose, lactose, a superdisintegrant, colloidal silicon dioxide, and magnesium stearate can reduce manufacturing steps and solvent exposure. It may also support high-throughput production.

The main risk is blend segregation caused by the low-dose, micronized active ingredient. Content uniformity must be demonstrated across the batch, including beginning, middle, and end-of-run samples. Ordered mixing, pre-blending, carrier selection, and controlled transfer are likely to be more important than simply increasing lubricant or glidant concentration.

4. Enabling excipient or solid-dispersion approach

A developer could pursue amorphous solid dispersion, lipid-based delivery, cyclodextrin complexation, or nanocrystal technology. These approaches may improve dissolution and reduce food sensitivity.

They are less attractive for a straightforward YONSA generic because they may introduce:

• New critical quality attributes.
• Physical stability concerns.
• More complex scale-up.
• Additional bioequivalence risk.
• Greater CMC documentation.
• Potential formulation patent exposure.

These technologies have higher platform value if they can support multiple poorly soluble oncology drugs, but they are less efficient when the commercial objective is a direct abiraterone acetate tablet.

What formulation patents protect YONSA?

YONSA’s defensible differentiation is associated primarily with micronized abiraterone acetate and the resulting dosage form and administration profile. The commercial protection can include several patent categories:

Patent category	Potential protected subject matter	Commercial relevance
Drug-substance particle engineering	Micronized abiraterone acetate, particle-size distribution, surface area	Supports reduced food effect and dissolution
Pharmaceutical composition	Abiraterone acetate combined with specified excipients	Can restrict close formulation copying
Dosage form	125 mg tablets and defined dose regimens	Supports product-specific substitution barriers
Method of treatment	Use with corticosteroid for prostate cancer	May create method-of-use litigation risk
Manufacturing process	Milling, blending, granulation, compression, or coating parameters	Can create process-development barriers
Stability and packaging	Moisture protection and product shelf life	Usually weaker as a standalone barrier

The public FDA Orange Book is the controlling source for listed patents and regulatory exclusivity. Small-molecule products such as YONSA do not receive biosimilar protection because biosimilar approval applies to biological products, not chemically synthesized abiraterone acetate. [3]

A formulation patent may be commercially important even when the active ingredient is no longer protected by compound patent rights. Its practical strength depends on claim breadth, prosecution history, written-description support, enablement, validity under obviousness standards, and whether a generic product can design around the claimed particle-size or composition limitations.

When does YONSA lose exclusivity and what generic entry risks exist?

YONSA received FDA approval in May 2018. The relevant exclusivity and patent timeline is not determined by approval date alone. It depends on listed Orange Book patents, patent-term adjustment, pediatric exclusivity, regulatory exclusivity, and the timing of any Paragraph IV challenge. [3,4]

Event	Relevance
May 2018 FDA approval	Starts the product’s commercial and regulatory timeline
Four-year NCE filing restriction	Relevant only if the product qualified for new chemical entity status
Five-year NCE exclusivity	Can delay certain ANDA filings if applicable
Orange Book patent listing	Determines the patent certification framework
Paragraph IV certification	Can trigger patent litigation and a 30-month stay
30-month stay	May delay ANDA approval, subject to court and FDA events
Patent expiration	Removes the relevant listed patent barrier
Pediatric exclusivity	Can add six months to qualifying exclusivity or patent terms

The principal generic-entry scenarios are:

1. A direct 125 mg micronized tablet with a formulation designed to match YONSA’s performance.
2. A 250 mg or 500 mg abiraterone acetate tablet positioned against ZYTIGA rather than YONSA.
3. A product using a different particle-engineering platform and seeking approval through an alternative regulatory route.
4. A settlement-based entry following Paragraph IV litigation.
5. A post-expiration launch after listed patents no longer block approval.

Generic competition against conventional abiraterone acetate tablets does not automatically eliminate YONSA’s commercial differentiation. YONSA’s food-flexible labeling, lower tablet strength, and methylprednisolone regimen may preserve demand in patients and practices that value administration convenience.

What is the FDA regulatory status and Orange Book position of YONSA?

YONSA is an FDA-approved prescription drug marketed as an oral tablet. Its regulatory reference is NDA 209579, according to FDA product information. [1,5]

The regulatory issues most relevant to a generic developer are:

• Demonstrating pharmaceutical equivalence.
• Establishing bioequivalence to the appropriate reference product.
• Matching the approved strength and dosage form.
• Addressing the micronized active ingredient.
• Demonstrating comparable dissolution.
• Managing the food-effect profile.
• Assessing whether inactive-ingredient differences affect absorption.
• Preparing patent certifications under the ANDA pathway.

A product intended to substitute for YONSA should not rely solely on comparison with ZYTIGA. YONSA and ZYTIGA contain the same active ingredient but have different formulation and food-administration characteristics. The reference product selected for an ANDA strategy must correspond to FDA’s product-specific regulatory requirements.

Which companies are challenging or competing with YONSA?

The relevant competitive set includes Sun Pharma’s YONSA, Janssen’s ZYTIGA, and generic abiraterone acetate manufacturers. Generic competition is likely to come from companies with established oncology, oral-solid-dose, and ANDA capabilities, including large Indian and global generics manufacturers.

Competition occurs across several dimensions:

Competitive factor	YONSA position	Generic opportunity
Dose size	Four 125 mg tablets daily	Lower manufacturing cost or alternative strength
Food administration	With or without food	Match label or compete on price
Active ingredient	Micronized abiraterone acetate	Reproduce particle engineering or develop a workaround
Steroid regimen	Methylprednisolone	Compete through prescriber familiarity and formulary positioning
Manufacturing	Controlled micronization and tablet processing	Use integrated API and finished-dose production
Payer economics	Branded specialty product	Discounted generic acquisition cost
Patent risk	Formulation and use claims	Design-around, Paragraph IV, or post-expiration entry

No biosimilar competition is relevant. The risk is generic substitution, reimbursement pressure, therapeutic switching, and erosion of branded market share.

What commercial opportunities exist for excipient suppliers?

The strongest excipient opportunities are functional rather than proprietary.

High-value opportunities

• Direct-compression grades with improved flow and low segregation.
• Low-peroxide and low-moisture excipients for stability-sensitive formulations.
• Surfactant grades optimized for wetting without excessive dissolution variability.
• Co-processed diluent-disintegrant systems.
• Lubricants that reduce ejection force without creating dissolution retardation.
• Excipient systems designed for micronized APIs.
• Technical services for powder characterization and scale-up.
• Particle-engineering services, including jet milling and air classification.
• Continuous manufacturing platforms for low-dose blend uniformity.
• Packaging systems that limit moisture and preserve tablet performance.

The commercial proposition is strongest when the supplier can provide a documented performance package covering compaction, flow, blend uniformity, dissolution, and stability. A commodity excipient with no differentiated technical data is exposed to price competition.

Manufacturing and IP barriers

API micronization is a more meaningful barrier than most individual excipients. A supplier able to control particle-size distribution at commercial scale, prevent agglomeration, and provide reproducible surface characteristics can become embedded in a generic developer’s CMC strategy.

Process know-how may also create practical barriers even where patent protection is limited. These include:

• Milling energy and residence time.
• Temperature control during micronization.
• Deagglomeration.
• Powder containment and occupational controls.
• Blend sequence.
• Lubrication time.
• Compression-force profile.
• Film-coating weight gain.
• In-process dissolution and content-uniformity testing.

How strong is the YONSA patent estate?

The estate is strongest where claims connect micronized abiraterone acetate to a measurable performance advantage, such as improved dissolution or reduced food effect. It is weaker where protection depends on routine excipient combinations or broad claims that can be challenged as obvious over known poorly soluble drug formulations.

Patent strength should be assessed through five factors:

1. Whether the claims require a narrow particle-size range.
2. Whether the claims cover the commercial formulation or only selected examples.
3. Whether a generic can use a different excipient system without infringing.
4. Whether the claims cover the method of administration with or without food.
5. Whether the patent survives obviousness, enablement, and written-description challenges.

A generic developer with an alternative micronization profile, different surfactant system, and noninfringing manufacturing process may reduce formulation patent exposure. That approach increases bioequivalence and development cost.

What revenue exposure does YONSA create for Sun Pharma?

YONSA is exposed to ordinary small-molecule erosion once generic products achieve approval and substitution. Revenue risk is likely to be greatest in payer-controlled channels, where pharmacy benefit managers can favor lower-cost abiraterone products.

The product has defenses that may slow direct substitution:

• Food-flexible administration.
• Distinct 125 mg tablet strength.
• Established oncology prescriber use.
• A differentiated steroid regimen.
• Potential formulation patent protection.
• Specialty-pharmacy distribution.
• Patient and practice familiarity with the product.

These defenses do not eliminate generic risk. Once a therapeutically and regulatorily substitutable generic is available, price competition can be rapid. The largest commercial uncertainty is whether generic developers target YONSA specifically or enter through conventional abiraterone acetate products first.

Key Takeaways

• YONSA’s formulation strategy is based on micronized abiraterone acetate, not a novel excipient.
• The critical technical objective is to control dissolution and food-effect behavior.
• Lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxide, and magnesium stearate form a conventional but performance-sensitive excipient system.
• Excipient grade, particle size, moisture, lubrication, and blend sequence can materially affect bioequivalence.
• The most attractive supplier opportunities involve functional excipients, micronization services, powder characterization, and scale-up support.
• Generic developers face both formulation-patent risk and practical manufacturing barriers.
• YONSA has no biosimilar exposure because abiraterone acetate is a small molecule.
• The Orange Book, FDA product-specific guidance, and current patent records control the timing of ANDA entry and Paragraph IV risk.

FAQs

Can YONSA be formulated without sodium lauryl sulfate?

Yes, but replacing sodium lauryl sulfate may change wetting, dissolution, exposure, and food-effect behavior. A replacement would require comparative formulation and bioequivalence support.

Is YONSA a nanomedicine?

No. YONSA is described as containing micronized abiraterone acetate. Micronization reduces particle size but does not by itself establish a nanoparticle or nanomedicine product classification.

Can a generic manufacturer use different excipients from YONSA?

Potentially. FDA permits inactive-ingredient differences when the product satisfies applicable pharmaceutical equivalence, bioequivalence, quality, safety, and regulatory requirements. The differences must not compromise performance or substitutability.

Does YONSA require a special package because of its excipients?

The product’s packaging must preserve tablet quality and stability. Moisture protection, container-closure integrity, and compatibility with the film-coated tablet are relevant, although the public label does not establish a uniquely mandated package technology.

Is a 250 mg abiraterone tablet automatically a substitute for YONSA?

No. YONSA is a 125 mg micronized tablet with a specific food-administration profile and steroid regimen. A 250 mg or 500 mg abiraterone product may be therapeutically related but is not automatically pharmaceutically equivalent or substitutable for YONSA.

References

1. U.S. Food and Drug Administration. (2024). YONSA (abiraterone acetate) tablets, prescribing information. Sun Pharmaceutical Industries, Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. U.S. Food and Drug Administration. (2024). ZYTIGA (abiraterone acetate) tablets, prescribing information. Janssen Biotech, Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov/drugs

5. U.S. Food and Drug Administration. (2018). FDA approves abiraterone acetate tablets for metastatic prostate cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/